OR WAIT null SECS
Susan Haigney is lead editor of BioPharm International®.
May 08, 2024
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
April 18, 2024
CordenPharma’s partnership with GENEPEP expedites lead development and validation in project phases, and its LNP β-sitosterol supports sustainable emission reduction targets.
April 17, 2024
The Xcellerex magnetic mixer, single-use mixing system was designed to address challenges in large-scale mAb, vaccine, and genomic medicine manufacturing processes.
April 16, 2024
The airlock solution for cleanrooms offers contamination controls for a highly controlled environment.
April 15, 2024
C3TI will promote CDER’s clinical trial innovation activities both internally and externally.
April 12, 2024
The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.